A rare strain of the Ebola virus, identified as the Bundibugyo species, is currently proliferating across the Democratic Republic of Congo (DRC) and Uganda, challenging existing public health infrastructures.

一種被鑑定為 Bundibugyo 菌株的罕見埃博拉病毒，目前正在剛果民主共和國（DRC）與烏干達蔓延，對現有的公共衛生基礎設施構成挑戰。

The current epidemiological crisis, characterized as the third-largest Ebola outbreak on record, originated in eastern DRC. Due to the rarity of the Bundibugyo strain, initial diagnostic efforts were unsuccessful, resulting in a detection lag from February until mid-May. This delay has exacerbated the risk of regional transmission. The virus's spread is further facilitated by increased human mobility via motorized transport and the high population density of the affected regions. Furthermore, the outbreak is superimposed upon a landscape of chronic instability; the Kivus region is currently a theater for regional conflict involving multiple sovereign states and armed factions competing for mineral resources. This volatility impedes the movement of responders and complicates the implementation of contact tracing, which currently remains below the 95% target benchmark.

目前的流行病危機被定格為紀錄以來第三大的埃博拉爆發，起源於剛果民主共和國東部。由於 Bundibugyo 菌株的罕見性，最初的診斷工作未能成功，導致偵測時間從二月延遲至五月中旬。此延遲加劇了區域傳播的風險。病毒的傳播更因機動交通增加的人員流動性以及受影響地區的高人口密度而加速。此外，此次爆發疊加在長期不穩定的局勢之上；Kivus 地區目前是多個主權國家與武裝派系爭奪礦產資源的區域衝突戰場。這種不穩定狀態阻礙了救援人員的行動，並使接觸者追蹤的執行複雜化，目前的追蹤率仍低於 95% 的目標基準。

Institutional responses have been characterized by a shift toward isolationism. While the WHO and Africa CDC have initiated a $518 million emergency response plan, there are significant concerns regarding the adequacy of funding. This is attributed to the diminution of the U.S. CDC's international role and the dismantling of USAID. Consequently, several nations have implemented border restrictions and travel bans. Critics argue that such measures prioritize national insulation over the eradication of the pathogen, suggesting that border containment is ineffective when upstream control fails. Additionally, deep-seated community mistrust—fueled by perceptions of the 'Ebola business' and the exploitative nature of foreign interventions—has led to the dissemination of misinformation and occasional violence against health facilities.

機構反應的特徵是向孤立主義轉移。雖然世界衛生組織（WHO）與非洲疾控中心（Africa CDC）啟動了一項 5.18 億美元的緊急應對計劃，但對於資金是否充足存在重大疑慮。這歸因於美國疾控中心（U.S. CDC）國際角色的縮減以及美國國際開發署（USAID）的解體。因此，數個國家實施了邊境限制與旅遊禁令。批評者認為此類措施優先考慮國家隔離而非根除病原體，暗示當上游控制失敗時，邊境封鎖是無效的。此外，深層的社區不信任——由對「埃博拉生意」的認知以及外國干預的剝削性質所驅動——導致了錯誤資訊的傳播以及偶發的針對醫療設施的暴力行為。

Medical countermeasures for the Bundibugyo strain are currently non-existent, as existing vaccines are ineffective. To address this deficit, a collaborative effort involving the WHO, Africa CDC, and academic institutions has commenced clinical trials. These trials are evaluating the repurposing of existing pharmaceuticals, specifically the antiviral remdesivir and the monoclonal antibody MBP-134 for treatment, and obeldesivir for post-exposure prophylaxis. The efficacy of these interventions remains contingent upon the ability of researchers to maintain secure clinical sites amidst ongoing regional conflict.

針對 Bundibugyo 菌株的醫療對策目前尚不存在，因為現有疫苗無效。為了彌補這一缺陷，由 WHO、非洲疾控中心及學術機構組成的協作團隊已開始臨床試驗。這些試驗正在評估現有藥物的重新用途，特別是使用抗病毒藥物 remdesivir 和單克隆抗體 MBP-134 進行治療，以及使用 obeldesivir 進行曝露後預防。這些干預措施的成效仍取決於研究人員在持續的區域衝突中能否維持安全的臨床試驗場地。

The outbreak remains active in the DRC and Uganda, with the potential for endemicity if international cooperation and targeted medical interventions fail to achieve total eradication.

此次爆發在剛果民主共和國與烏干達仍處於活躍狀態，若國際合作與針對性醫療干預未能實現全面根除，則有可能演變為地方性流行。